TABLE 3 from A Phase I/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma
收藏Figshare2023-06-08 更新2026-04-28 收录
下载链接：
https://figshare.com/articles/dataset/TABLE_3_from_A_Phase_I_II_Clinical_Trial_of_Pembrolizumab_and_Cabozantinib_in_Metastatic_Renal_Cell_Carcinoma/23393623
下载链接
链接失效反馈官方服务：
资源简介：
Best response by RECIST in evaluable patients treated at RP2D (pembrolizumab 200 mg i.v. every 3 weeks and cabozantinib 60 mg orally once daily).
创建时间：
2023-06-08
